Trial Profile
The efficacy of tolvaptan, a vasopressin V2 receptor antagonist, in patients with congestive heart failure and kidney diseases
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jun 2016
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure; Kidney disorders
- Focus Therapeutic Use
- 09 Jun 2016 New trial record